Grade My Investments
HomeFree Stock Grades › PROK

ProKidney Corp. (PROK) Stock Grade

PROK · Healthcare

A
Grade updated: July 18, 2026
Computed by the GradeMyInvestments scoring model from revenue growth, profitability, balance-sheet strength, and analyst targets.
Market Cap
$680.9M
P/E Ratio
Revenue Growth (YoY)
+1075.0%
Net Margin
-7725.2%
Return on Equity
6.8%
Dividend Yield
None

About ProKidney Corp.'s fundamentals

ProKidney Corp. is a biotechnology company with a market capitalization of $680.9 million that reported exceptional revenue growth of 1,075% year-over-year, indicating rapidly expanding commercial activity. However, the company posted a net loss in its latest annual statement, resulting in a net margin of -7,725.2%, reflecting significant operating expenses that currently exceed revenues. The company does not pay a dividend and has a return on equity of 6.8%, suggesting modest efficiency in deploying shareholder capital despite ongoing losses.

Track PROK free — no credit card required. Live grade + monthly AI report →